A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates

Stephen Israel Rennard, John Hughes, Paul M. Cinciripini, Eva Kralikova, Tobias Raupach, Carmen Arteaga, Lisa B. St Aubin, Cristina Russ

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Introduction: Current smoking cessation guidelines recommend setting a quit date prior to starting pharmacotherapy. However, providing flexibility in the date of quitting may be more acceptable to some smokers. The objective of this study was to compare varenicline 1 mg twice daily (b.i.d.) with placebo in subjects using a flexible quit date paradigm after starting medication. Methods: In this double-blind, randomized, placebo-controlled international study, smokers of ≥10 cigarettes/day, aged 18-75 years, and who were motivated to quit were randomized (3:1) to receive varenicline 1 mg b.i.d. or placebo for 12 weeks. Subjects were followed up through Week 24. Subjects were instructed to quit between Days 8 and 35 after starting medication. The primary endpoint was carbon monoxide-confirmed continuous abstinence during Weeks 9-12, and a key secondary endpoint was continuous abstinence during Weeks 9-24. Results: Overall, 493 subjects were randomized to varenicline and 166 to placebo. Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9-12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7-9.4; p < .0001) and through 24 weeks follow-up (Weeks 9-24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6-7.5; p < .0001). Serious adverse events occurred in 1.2% varenicline (none were psychiatric) and 0.6% placebo subjects. Fewer varenicline than placebo subjects reported depression-related adverse events (2.3% vs. 6.7%, respectively). Conclusions: Varenicline 1 mg b.i.d. using a flexible quit date paradigm had similar efficacy and safety compared with previous fixed quit date studies.

Original languageEnglish (US)
Pages (from-to)343-350
Number of pages8
JournalNicotine and Tobacco Research
Volume14
Issue number3
DOIs
StatePublished - Mar 6 2012

Fingerprint

Smoking Cessation
Randomized Controlled Trials
Placebos
Odds Ratio
Carbon Monoxide
Varenicline
Double-Blind Method
Tobacco Products
Psychiatry
Guidelines
Safety
Drug Therapy

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Rennard, S. I., Hughes, J., Cinciripini, P. M., Kralikova, E., Raupach, T., Arteaga, C., ... Russ, C. (2012). A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine and Tobacco Research, 14(3), 343-350. https://doi.org/10.1093/ntr/ntr220

A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. / Rennard, Stephen Israel; Hughes, John; Cinciripini, Paul M.; Kralikova, Eva; Raupach, Tobias; Arteaga, Carmen; St Aubin, Lisa B.; Russ, Cristina.

In: Nicotine and Tobacco Research, Vol. 14, No. 3, 06.03.2012, p. 343-350.

Research output: Contribution to journalArticle

Rennard, SI, Hughes, J, Cinciripini, PM, Kralikova, E, Raupach, T, Arteaga, C, St Aubin, LB & Russ, C 2012, 'A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates', Nicotine and Tobacco Research, vol. 14, no. 3, pp. 343-350. https://doi.org/10.1093/ntr/ntr220
Rennard, Stephen Israel ; Hughes, John ; Cinciripini, Paul M. ; Kralikova, Eva ; Raupach, Tobias ; Arteaga, Carmen ; St Aubin, Lisa B. ; Russ, Cristina. / A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. In: Nicotine and Tobacco Research. 2012 ; Vol. 14, No. 3. pp. 343-350.
@article{f092b0d3d2b54acf95b660f4c1457521,
title = "A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates",
abstract = "Introduction: Current smoking cessation guidelines recommend setting a quit date prior to starting pharmacotherapy. However, providing flexibility in the date of quitting may be more acceptable to some smokers. The objective of this study was to compare varenicline 1 mg twice daily (b.i.d.) with placebo in subjects using a flexible quit date paradigm after starting medication. Methods: In this double-blind, randomized, placebo-controlled international study, smokers of ≥10 cigarettes/day, aged 18-75 years, and who were motivated to quit were randomized (3:1) to receive varenicline 1 mg b.i.d. or placebo for 12 weeks. Subjects were followed up through Week 24. Subjects were instructed to quit between Days 8 and 35 after starting medication. The primary endpoint was carbon monoxide-confirmed continuous abstinence during Weeks 9-12, and a key secondary endpoint was continuous abstinence during Weeks 9-24. Results: Overall, 493 subjects were randomized to varenicline and 166 to placebo. Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9-12: 53.1{\%} vs. 19.3{\%}; odds ratio [OR] 5.9; 95{\%} CI, 3.7-9.4; p < .0001) and through 24 weeks follow-up (Weeks 9-24: 34.7{\%} vs. 12.7{\%}; OR 4.4; 95{\%} CI, 2.6-7.5; p < .0001). Serious adverse events occurred in 1.2{\%} varenicline (none were psychiatric) and 0.6{\%} placebo subjects. Fewer varenicline than placebo subjects reported depression-related adverse events (2.3{\%} vs. 6.7{\%}, respectively). Conclusions: Varenicline 1 mg b.i.d. using a flexible quit date paradigm had similar efficacy and safety compared with previous fixed quit date studies.",
author = "Rennard, {Stephen Israel} and John Hughes and Cinciripini, {Paul M.} and Eva Kralikova and Tobias Raupach and Carmen Arteaga and {St Aubin}, {Lisa B.} and Cristina Russ",
year = "2012",
month = "3",
day = "6",
doi = "10.1093/ntr/ntr220",
language = "English (US)",
volume = "14",
pages = "343--350",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates

AU - Rennard, Stephen Israel

AU - Hughes, John

AU - Cinciripini, Paul M.

AU - Kralikova, Eva

AU - Raupach, Tobias

AU - Arteaga, Carmen

AU - St Aubin, Lisa B.

AU - Russ, Cristina

PY - 2012/3/6

Y1 - 2012/3/6

N2 - Introduction: Current smoking cessation guidelines recommend setting a quit date prior to starting pharmacotherapy. However, providing flexibility in the date of quitting may be more acceptable to some smokers. The objective of this study was to compare varenicline 1 mg twice daily (b.i.d.) with placebo in subjects using a flexible quit date paradigm after starting medication. Methods: In this double-blind, randomized, placebo-controlled international study, smokers of ≥10 cigarettes/day, aged 18-75 years, and who were motivated to quit were randomized (3:1) to receive varenicline 1 mg b.i.d. or placebo for 12 weeks. Subjects were followed up through Week 24. Subjects were instructed to quit between Days 8 and 35 after starting medication. The primary endpoint was carbon monoxide-confirmed continuous abstinence during Weeks 9-12, and a key secondary endpoint was continuous abstinence during Weeks 9-24. Results: Overall, 493 subjects were randomized to varenicline and 166 to placebo. Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9-12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7-9.4; p < .0001) and through 24 weeks follow-up (Weeks 9-24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6-7.5; p < .0001). Serious adverse events occurred in 1.2% varenicline (none were psychiatric) and 0.6% placebo subjects. Fewer varenicline than placebo subjects reported depression-related adverse events (2.3% vs. 6.7%, respectively). Conclusions: Varenicline 1 mg b.i.d. using a flexible quit date paradigm had similar efficacy and safety compared with previous fixed quit date studies.

AB - Introduction: Current smoking cessation guidelines recommend setting a quit date prior to starting pharmacotherapy. However, providing flexibility in the date of quitting may be more acceptable to some smokers. The objective of this study was to compare varenicline 1 mg twice daily (b.i.d.) with placebo in subjects using a flexible quit date paradigm after starting medication. Methods: In this double-blind, randomized, placebo-controlled international study, smokers of ≥10 cigarettes/day, aged 18-75 years, and who were motivated to quit were randomized (3:1) to receive varenicline 1 mg b.i.d. or placebo for 12 weeks. Subjects were followed up through Week 24. Subjects were instructed to quit between Days 8 and 35 after starting medication. The primary endpoint was carbon monoxide-confirmed continuous abstinence during Weeks 9-12, and a key secondary endpoint was continuous abstinence during Weeks 9-24. Results: Overall, 493 subjects were randomized to varenicline and 166 to placebo. Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9-12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7-9.4; p < .0001) and through 24 weeks follow-up (Weeks 9-24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6-7.5; p < .0001). Serious adverse events occurred in 1.2% varenicline (none were psychiatric) and 0.6% placebo subjects. Fewer varenicline than placebo subjects reported depression-related adverse events (2.3% vs. 6.7%, respectively). Conclusions: Varenicline 1 mg b.i.d. using a flexible quit date paradigm had similar efficacy and safety compared with previous fixed quit date studies.

UR - http://www.scopus.com/inward/record.url?scp=84857676788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857676788&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntr220

DO - 10.1093/ntr/ntr220

M3 - Article

VL - 14

SP - 343

EP - 350

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 3

ER -